Related Experiment Video
Updated: Aug 13, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
A phase II study of ifosfamide in children with recurrent solid tumours
Cancer Chemotherapy and Pharmacology
|January 1, 1985
Summary
Ifosfamide chemotherapy showed promise in treating pediatric cancers like Wilms' tumor and Ewing's sarcoma, with some patients achieving complete responses. Further research is recommended to explore its efficacy in combination therapies.
Area of Science:
- Pediatric Oncology
- Medical Chemistry
Background:
- Recurrent or unresponsive pediatric tumors pose significant treatment challenges.
- Previous chemotherapy regimens, often including cyclophosphamide, may have limitations.
Purpose of the Study:
- To evaluate the efficacy and tolerability of ifosfamide in children with various recurrent or unresponsive solid tumors.
- To assess ifosfamide pharmacokinetics in pediatric patients.
Main Methods:
- A single-arm study administering ifosfamide (5 mg/m2) as a 24-h infusion with mesna uroprotection to 21 children.
- Patients received 1-13 courses (median 3) every 2-3 weeks.
- Plasma ifosfamide levels were measured using gas-liquid chromatography.
Main Results:
- Complete clinical responses were observed in 3 patients (2 Wilms', 1 Ewing's), lasting 5-9 months.
- Partial responses occurred in 3 patients; stable disease in 4; progressive disease in 11.
- Treatment was generally well-tolerated, with manageable side effects like transient neurological symptoms and hypertension. No cystitis or severe myelosuppression was noted.
Conclusions:
- Ifosfamide demonstrates activity in pediatric solid tumors, including Wilms' and Ewing's sarcoma.
- Pharmacokinetic data suggest a shorter elimination half-life in children compared to adults.
- Ifosfamide-containing combination chemotherapy warrants investigation as a potential front-line treatment option.
